Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$447K Sell
3,263
-1,542
-32% -$212K 0.36% 54
2024
Q3
$487K Sell
4,805
-40
-0.8% -$3.16K 0.37% 50
2024
Q2
$354K Sell
4,845
-14,128
-74% -$926K 0.29% 57
2024
Q1
$959K Buy
18,973
+636
+3% +$29.8K 0.72% 36
2023
Q4
$858K Buy
18,337
+97
+0.5% +$4.42K 0.71% 35
2023
Q3
$830K Buy
18,240
+651
+4% +$26.9K 0.67% 37
2023
Q2
$693K Buy
17,589
+377
+2% +$15.3K 0.54% 36
2023
Q1
$697K Buy
+17,212
New +$676K 0.54% 38

Other funds holding AGX

Keene & Associates's AGX Position: Q4 2024 in Review

Keene & Associates reduced its Argan (AGX) stake by 32% in Q4 2024, selling an estimated $212K and leaving 3,263 shares worth $447K. The position accounts for 0.36% of the portfolio, ranked #54.

Keene & Associates first reported a position in AGX in Q1 2023 and has held it in 8 quarters since. The position peaked at $959K in Q1 2024. 276 funds tracked by Wall St. Rank hold AGX as of Q4 2024.

  • Keene & Associates held 3,263 shares of Argan worth $447K as of Q4 2024.
  • Keene & Associates sold 1,542 Argan shares in Q4 2024, an estimated $212K.
  • Argan made up 0.36% of Keene & Associates's portfolio in Q4 2024, its #54 holding.
  • Keene & Associates first reported a position in Argan in Q1 2023 and has held it in 8 quarters since.
  • Keene & Associates's Argan position peaked at $959K in Q1 2024.
  • 276 funds tracked by Wall St. Rank held Argan as of Q4 2024.

Based on Keene & Associates's 13F filing for Q4 2024, filed 3 Feb 2025.